122 related articles for article (PubMed ID: 38622987)
1. The prevalence and clinical significance of HER2 expression in prostate adenocarcinoma.
Estephan F; Lap CJ; Banagan J; Antonio M; Liu S; Diao G; Rozalen AZ; Rajendran R; Krasnow S; Subrahmanyam R; Nava VE; Jain M
Ann Diagn Pathol; 2023 Dec; 67():152219. PubMed ID: 38622987
[TBL] [Abstract][Full Text] [Related]
2. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A
Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer.
Minner S; Jessen B; Stiedenroth L; Burandt E; Köllermann J; Mirlacher M; Erbersdobler A; Eichelberg C; Fisch M; Brümmendorf TH; Bokemeyer C; Simon R; Steuber T; Graefen M; Huland H; Sauter G; Schlomm T
Clin Cancer Res; 2010 Mar; 16(5):1553-60. PubMed ID: 20179235
[TBL] [Abstract][Full Text] [Related]
5. HER2 in gastric cancer: comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays.
Abrahão-Machado LF; Jácome AA; Wohnrath DR; dos Santos JS; Carneseca EC; Fregnani JH; Scapulatempo-Neto C
World J Gastroenterol; 2013 Oct; 19(38):6438-46. PubMed ID: 24151362
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric MRI in detection and staging of prostate cancer.
Boesen L
Dan Med J; 2017 Feb; 64(2):. PubMed ID: 28157066
[TBL] [Abstract][Full Text] [Related]
7. Her2 expression in prostatic cancer: a comparison with mammary carcinoma.
Jorda M; Morales A; Ghorab Z; Fernandez G; Nadji M; Block N
J Urol; 2002 Oct; 168(4 Pt 1):1412-4. PubMed ID: 12352406
[TBL] [Abstract][Full Text] [Related]
8. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival.
Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O
Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613
[TBL] [Abstract][Full Text] [Related]
9. Adenocarcinoma of the prostate with Gleason pattern 5 on core biopsy: frequency of diagnosis, morphologic subpatterns, and relation to pattern distribution based on the modified Gleason grading system.
Shah RB; Tadros Y
Hum Pathol; 2014 Nov; 45(11):2263-9. PubMed ID: 25228336
[TBL] [Abstract][Full Text] [Related]
10. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients.
Abu Al Karsaneh O; Al Anber A; ALQudah M; Al-Mustafa S; AlMa'aitah H; Sughayer M
Diagn Pathol; 2023 Jun; 18(1):75. PubMed ID: 37340403
[TBL] [Abstract][Full Text] [Related]
13. Interobserver and Interantibody Reproducibility of HER2 Immunohistochemical Scoring in an Enriched HER2-Low-Expressing Breast Cancer Cohort.
Karakas C; Tyburski H; Turner BM; Wang X; Schiffhauer LM; Katerji H; Hicks DG; Zhang H
Am J Clin Pathol; 2023 May; 159(5):484-491. PubMed ID: 36856777
[TBL] [Abstract][Full Text] [Related]
14. Comparison of HER2 immunohistochemical results using a monoclonal antibody (SV2-61γ) and a polyclonal antibody (for Dako HercepTest) in advanced gastric cancer.
Tamura G; Osakabe M; Yanagawa N; Ogata SY; Nomura T; Fukushima N; Ito Y; Tabuchi M
Pathol Int; 2012 Aug; 62(8):513-7. PubMed ID: 22827758
[TBL] [Abstract][Full Text] [Related]
15. HER2 gene amplification in patients with prostate cancer: Evaluating a CISH-based method.
Sharifi N; Salmaninejad A; Ferdosi S; Bajestani AN; Khaleghiyan M; Estiar MA; Jamali M; Nowroozi MR; Shakoori A
Oncol Lett; 2016 Dec; 12(6):4651-4658. PubMed ID: 28105172
[TBL] [Abstract][Full Text] [Related]
16. Immuno-Histochemical Assessment of HER2NEU Expression in Gastric Adenocarcinoma in North Karnataka, India.
Nadaf AS; Rani H; Dinesh US
Asian Pac J Cancer Prev; 2018 May; 19(5):1381-1385. PubMed ID: 29802704
[TBL] [Abstract][Full Text] [Related]
17. Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.
Robbins CJ; Fernandez AI; Han G; Wong S; Harigopal M; Podoll M; Singh K; Ly A; Kuba MG; Wen H; Sanders MA; Brock J; Wei S; Fadare O; Hanley K; Jorns J; Snir OL; Yoon E; Rabe K; Soong TR; Reisenbichler ES; Rimm DL
Mod Pathol; 2023 Jan; 36(1):100032. PubMed ID: 36788069
[TBL] [Abstract][Full Text] [Related]
18. Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
Hofmann M; Stoss O; Shi D; Büttner R; van de Vijver M; Kim W; Ochiai A; Rüschoff J; Henkel T
Histopathology; 2008 Jun; 52(7):797-805. PubMed ID: 18422971
[TBL] [Abstract][Full Text] [Related]
19. HER2 in resected gastric cancer: Is there prognostic value?
Fisher SB; Fisher KE; Squires MH; Patel SH; Kooby DA; El-Rayes BF; Cardona K; Russell MC; Staley CA; Farris AB; Maithel SK
J Surg Oncol; 2014 Feb; 109(2):61-6. PubMed ID: 24122802
[TBL] [Abstract][Full Text] [Related]
20. Analytical validation of human epidermal growth factor receptor 2 immunohistochemistry by the use of the A0485 antibody versus the 4B5 antibody and breast versus gastric scoring guidelines in ovarian clear cell carcinoma.
Lin SY; Wang YH; Hsu CY; Chen YJ; Lai CR; Hang JF
Histopathology; 2021 Nov; 79(5):758-767. PubMed ID: 34036622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
